Premium
O3‐03‐04: Identifying protein biomarkers for early diagnosis of Alzheimer's disease
Author(s) -
Doecke James,
Buckley Mike,
Good Norm,
Laws Simon,
Faux Noel,
Dunne Rob,
Wilson William,
Bush A.,
Ames David,
Ellis Kathryn,
Rowe Christopher,
Szoeke Cassandra,
Martins Ralph,
Masters Colin
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.407
Subject(s) - biomarker , disease , medicine , analyte , oncology , bioinformatics , biology , chemistry , biochemistry
was used to validate iTRAQ data. Results: In three replicate iTRAQ experiments ten proteins were significantly deregulated in MCI and AD plasma, relative to controls. These proteins included; apolipoprotein B-100, complement C3, C4b-binding protein, afamin, vitamin D-binding protein precursor, isoform 1 of Gelsolin actin regulator, Ig mu chain C region (IGHM protein), histidine-rich glycoprotein, fibrinogen beta and gamma chains. Western-blotting confirmed that afamin was decreased in the AD group, and IGHM was increased in aMCI+amdMCI and AD. Conclusions: These findings demonstrate that expression level changes are observed to multiple proteins in MCI and AD plasma. Some of these, such as afamin and IGHM, may be candidate biomarkers for AD and preclinical conditions such as MCI.